Profile data is unavailable for this security.
About the company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
- Revenue in CHF (TTM)63.28bn
- Net income in CHF12.42bn
- Incorporated1966
- Employees103.61k
- LocationRoche Holding AGGrenzacherstrasse 124BASEL 4058SwitzerlandCHE
- Phone+41 9 732354295
- Websitehttps://www.roche.com/
Mergers & acquisitions
Acquired company | ROG:SWX since announced | Transaction value |
---|---|---|
Good Therapeutics Inc | -19.41% | 250.00m |
Holder | Shares | % Held |
---|---|---|
APG Asset Management NVas of 31 Dec 2021 | 1.43m | 1.34% |
Canada Pension Plan Investment Boardas of 31 Mar 2022 | 1.29m | 1.21% |
RBC Global Asset Management (UK) Ltd.as of 31 Dec 2021 | 983.99k | 0.92% |
The Vanguard Group, Inc.as of 03 Mar 2023 | 891.95k | 0.84% |
Credit Suisse Asset Management (Schweiz) AGas of 28 Feb 2023 | 811.33k | 0.76% |
UBS Asset Management Switzerland AGas of 28 Feb 2023 | 752.79k | 0.71% |
BlackRock Fund Advisorsas of 01 Mar 2023 | 681.56k | 0.64% |
Ignis Investment Services Ltd.as of 31 Jul 2022 | 492.84k | 0.46% |
BlackRock Advisors (UK) Ltd.as of 01 Mar 2023 | 225.82k | 0.21% |
Vontobel Asset Management AGas of 28 Feb 2023 | 210.78k | 0.20% |